HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene.

Abstract
Hypoxia-inducible factor-1 (HIF-1) plays a central role in cellular response to hypoxia by activating vascular endothelial growth factor (VEGF) and other angiogenic factors. Prolyl hydroxylase domain-2 (PHD2) protein induces the degradation of HIF-1 by hydroxylating specific prolyl residues. Therefore gene silencing of PHD2 by RNA interference (RNAi) might increase the expression of angiogenic growth factors and, consequently, neoangiogenesis through the stabilization of HIF-1alpha. In this study we have shown that the specific silencing of PHD2 is sufficient for stabilizing HIF-1alpha and increasing its transcriptional activity, resulting in the increased expression of angiogenic factors including VEGF and fibroblast growth factor-2 (FGF2). Moreover, when PHD2-siRNA vector was used, the increase in VEGF secretion was observed for as long as 18 days after transfection. In vitro treatment of human umbilical vein endothelical cells with conditioned medium from PHD2-siRNA vector-transfected NIH3T3 cells was shown to increase cell proliferation. Also, in vivo angiogenesis was observed in mice implanted with Matrigel plugs mixed with NIH3T3 cells transfected with PHD2-siRNA vector. These results indicate that PHD2 silencing induces expressions of multiple angiogenic growth factors by stabilizing HIF-1alpha, and that the implantation of cells transfected with PHD2-siRNA vector is sufficient to enhance angiogenesis in vivo. In the light of these findings, PHD2 silencing by RNAi might offer a potential tool for angiogenic therapy.
AuthorsShourong Wu, Nobuhiro Nishiyama, Mitsunobu R Kano, Yasuyuki Morishita, Kohei Miyazono, Keiji Itaka, Ung-Il Chung, Kazunori Kataoka
JournalMolecular therapy : the journal of the American Society of Gene Therapy (Mol Ther) Vol. 16 Issue 7 Pg. 1227-34 (Jul 2008) ISSN: 1525-0024 [Electronic] United States
PMID18500250 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • DNA-Binding Proteins
  • Hif1a protein, mouse
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Immediate-Early Proteins
  • RNA, Small Interfering
  • Vascular Endothelial Growth Factor A
  • Procollagen-Proline Dioxygenase
  • Egln1 protein, mouse
  • Hypoxia-Inducible Factor-Proline Dioxygenases
Topics
  • Animals
  • Cell Proliferation
  • DNA-Binding Proteins (antagonists & inhibitors, genetics)
  • Female
  • Gene Expression Regulation
  • Genetic Therapy
  • Humans
  • Hypoxia-Inducible Factor 1, alpha Subunit (genetics, metabolism)
  • Hypoxia-Inducible Factor-Proline Dioxygenases
  • Immediate-Early Proteins (antagonists & inhibitors, genetics)
  • Mice
  • Mice, Inbred BALB C
  • NIH 3T3 Cells
  • Neovascularization, Physiologic (genetics)
  • Procollagen-Proline Dioxygenase
  • RNA Interference
  • RNA, Small Interfering (genetics)
  • Vascular Endothelial Growth Factor A (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: